利元亨(688499.SH):中標蜂巢能源8.76億元的鋰電生產設備項目
格隆匯12月1日丨利元亨(688499.SH)公佈,公司於2021年11月25日至公吿披露日陸續收到《中標通知》,公司中標蜂巢能源科技有限公司(“蜂巢能源”)在湖州、遂寧、馬鞍山、南京、鹽城、上饒、金壇等基地的鋰電生產設備項目,合計中標金額約8.76億元。
公司此次蜂巢能源合計中標金額約8.76億元,此次中標有利於公司在新能源動力電池領域的業務拓展,提高公司收入規模及盈利能力,對公司2021年度經營業績不會構成重大影響,預計將對公司未來年度的經營業績產生積極影響,具體影響金額及影響時間將視交易的具體情況而定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.